On July 3rd, Samsung Bioepis announced that it had released its Humira biosimilar ‘Hadlima (project name: SB5, ingredient: adalimumab) in the US through its partner Organon.

Hadlima is a treatment for autoimmune diseases including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.

The drug is now available in the US in two formulations – low concentration (50 mg/mL) and high concentration (100mg/mL) – and is supplied in a carton containing two pre-filled pens or two